Welcome to our dedicated page for Zentalis Pharmaceuticals SEC filings (Ticker: ZNTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Zentalis Pharmaceuticals, Inc. SEC filings document clinical oncology disclosures, financial results, governance matters and capital actions for the ZNTL public company. Recent Form 8-K filings cover azenosertib program updates, Regulation FD corporate presentations, clinical-trial and scientific-presentation exhibits, and results of operations furnished with business updates.
The company’s proxy materials describe board composition, executive compensation, equity awards and shareholder voting matters. Other event filings also record corporate governance changes and completed common stock repurchase activity, alongside cautionary risk language related to clinical development, regulatory pathways and forward-looking statements.
Zentalis Pharmaceuticals (ZNTL) Director Jan Skvarka received a grant of 57,603 restricted stock units (RSUs) on June 17, 2025, as part of the company's Non-Employee Director Compensation Program. Following this transaction, Skvarka now beneficially owns 207,154 shares directly.
Key details of the RSU grant:
- Each RSU represents a contingent right to receive one share of common stock
- Vesting occurs at the earlier of June 17, 2026 or the next annual stockholder meeting
- Vesting is contingent on continued service on the Board of Directors
- The RSUs were granted at $0 exercise price
This Form 4 filing was submitted by Andrea Paul as attorney-in-fact for Jan Skvarka on June 18, 2025, in compliance with SEC insider trading reporting requirements.
Zentalis Pharmaceuticals (ZNTL) Director David Michael Johnson reported acquiring 57,603 restricted stock units (RSUs) on June 17, 2025. The RSUs were granted under the company's Non-Employee Director Compensation Program at a price of $0.
Key details of the transaction:
- Following the transaction, Johnson directly owns 250,421 shares
- The RSUs will vest on the earlier of June 17, 2026 or the next annual stockholder meeting
- Vesting is contingent on Johnson's continued service on the Board of Directors
- Each RSU represents the right to receive one share of common stock upon vesting
The Form 4 was filed on June 28, 2025, with the signature executed by Andrea Paul as attorney-in-fact for David M. Johnson on June 18, 2025.
Zentalis Pharmaceuticals (NASDAQ: ZNTL) held its 2025 Annual Meeting of Stockholders on June 17, with 80.9% of outstanding shares represented. Key voting results include:
- Director Elections: Three Class II directors were elected to serve until 2028: - Scott Myers (43M votes for) - Karan Takhar (30.7M votes for) - Luke Walker, M.D. (36.6M votes for)
- Auditor Ratification: Ernst & Young LLP appointment was approved with overwhelming support (58.1M votes for, representing 99.8% approval)
- Executive Compensation: The "Say-on-Pay" vote passed but with significant opposition - 62.9% in favor (29.5M votes) versus 37.1% against (17.4M votes), indicating substantial shareholder concerns about executive compensation practices
The meeting results suggest strong shareholder engagement but reveal notable dissent regarding executive compensation and varying levels of support for board nominees, particularly for Karan Takhar who received the lowest approval rate among directors.